Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years

    August 21, 2026

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

    August 21, 2026
    Facebook X (Twitter) Instagram
    Pro KhaleejPro Khaleej
    • Home
    • Contact Us
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Pro KhaleejPro Khaleej
    Home » Innovative experimental malaria drug based on antibodies discovered
    Featured News

    Innovative experimental malaria drug based on antibodies discovered

    November 1, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Telegram Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    A new study in Africa has found that a one-time dose of an experimental drug protects adults against malaria for at least six months. In 2020, malaria killed more than 620,000 people and sickened 241 million, mostly children under 5. There is a malaria vaccine being rolled out by the World Health Organization for children, but it is only 30% effective and requires four doses.

    Innovative experimental malaria drug based on antibodies discoveredIn this new study, people received a large dose of lab-made malaria-fighting antibodies instead of relying on the immune system to make enough of those same infection-blockers after vaccination, reported the Associated Press (AP). “There are not enough people protected by the vaccine available,” said Kassoum Kayentao, a researcher from the University of Sciences, Techniques and Technologies in Bamako, Mali.

    In those villages, people are bitten by infected mosquitoes on average twice a day during malaria season, according to other research. Experimental antibody, developed by researchers at the US National Institutes of Health, was delivered by IV. In the meantime, an easy-to-administer shot version from the same scientists is in early testing in infants, children, and adults.

    Research presented at a medical meeting in Seattle was published Monday in the New England Journal of Medicine. In order to work, the antibody breaks the life cycle of the parasite, which is spread through mosquito bites. It targets immature parasites before they mature and multiply in the liver. An antibody taken from a volunteer who received a malaria vaccine was used to develop it.

    It involved 330 adults in Mali who received either a dummy infusion or two different antibody doses. Every two weeks for 24 weeks, all were tested for malaria infection. Treatment was provided to anyone who became ill. A blood test detected infections in 20 people who received the higher dose, 39 people who received the lower dose, and 86 people who received the placebo. Compared to the placebo, the higher dose was 88% effective. There was a 75% effectiveness rate for the lower dose.

    During a malaria season, protection might last for several months. In the future, it could be used in conjunction with other malaria prevention methods, such as malaria pills, mosquito nets, and vaccinations. According to one estimate, lab-made antibodies could be given for as little as $5 per child per malaria season.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Thumbay International Pathway – MD Program, With Installments and a Direct Route to Residency in Romania

    August 21, 2026

    SOUEAST UAE launches S08 Luxury following the success of the Flagship S08DM

    August 19, 2026

    Papa Johns teams up with Disney and Pixar for Toy Story 5

    August 7, 2026

    Risk-On or Risk-Off? How to Read Global Sentiment Before You Trade

    July 20, 2026

    Bond Yields Are Moving FX More Than Headlines – Here’s Why

    July 13, 2026

    Tamchy Special Financial Investment Territory on Issyk-Kul Launched in Kyrgyzstan

    July 6, 2026
    Latest News
    Business

    Wall Street rises after Treasury expands debt buybacks

    August 20, 2026

    U.S. stocks ended modestly higher Wednesday as long-term Treasury yields fell sharply. The S&P 500 rose 16.22 points, or 0.21%, to 7,707.98, ending a three-session losing streak. The Dow Jones Industrial Average gained 119.65 points, or 0.22%, to close at 53,463.05. The Nasdaq Composite added 41.38 points, or 0.16%, finishing at 26,331.09. Falling government bond yields helped major indexes recover after several sessions of pressure from rising borrowing costs. Bond prices climbed after the U.S. Treasury Department announced larger liquidity support buybacks for longer-dated government debt. Starting September 9, the maximum purchase size will increase from $2 billion to at least $4 billion per operation. The change covers nominal coupon securities in the 10-to-20-year and 20-to-30-year maturity sectors. The increased amounts will remain in effect through November 4. The department said strong volumes of high-quality offers supported the decision to increase liquidity operations in those sectors. Treasury yields moved lower following the announcement, reversing part of a recent rise in long-term borrowing costs. The 10-year Treasury yield fell to about 4.65%, while the 30-year yield declined to about 5.20%. The 30-year yield had reached 5.337% on Tuesday, its highest level since 2007. Bond yields move invers

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026
    © 2026 Pro Khaleej | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.